Tresivac Inj.(mmr)

TRESIVAC INJ. (MMR)

TRESIVAC® (Measles, Mumps, and Rubella Virus Vaccine (Live) I.P.) is a vaccine manufactured by the Serum Institute of India Pvt. Ltd. It is also available as TRESIVAC PFS.

Composition TRESIVAC® is a freeze-dried vaccine prepared from live, attenuated strains of Edmonston-Zagreb Measles virus, L-Zagreb Mumps virus, and Wistar RA 27/3 Rubella virus. Each single human dose of 0.5 ml, when reconstituted, contains not less than 1000 CCID50 of Measles virus, 5000 CCID50 of Mumps virus, and 1000 CCID50 of Rubella virus. The vaccine is provided with a diluent (Sterile Water for Injections).

Uses TRESIVAC® is indicated for active immunization against Measles, Mumps, and Rubella infections. It is primarily used for children from 9 months to 10 years of age, but can also be given to older children, adolescents, and susceptible non-pregnant adults who missed childhood vaccinations or have no record of vaccination. This vaccine works by stimulating the immune system to produce antibodies, providing protection against these viral diseases.

Dosage and Administration A single dose of 0.5 ml of the reconstituted vaccine is administered by deep subcutaneous injection. For toddlers, it is typically given into the anterolateral aspect of the upper thigh, and for older children, into the upper arm. The IAP Committee of Immunization recommends two doses for every child: the first at 9 months and the second between 15 to 18 months, or 4 to 8 weeks after the first dose. Some guidelines suggest a first dose at 12-15 months and a second dose at 4-6 years of age. Adults requiring vaccination should receive two doses with a minimum interval of four weeks. The vaccine must be reconstituted immediately before use with the provided diluent.

Side Effects Common side effects include pain, redness, or swelling at the injection site, low-grade fever, rash, temporary joint pain, and mild swelling of the glands. In adults, a higher percentage of adverse reactions, such as unilateral or bilateral parotitis and fever, can occur compared to childhood vaccination. Serious side effects like severe allergic reactions, seizures (associated with fever), and temporary low platelet count are rare.

Precautions TRESIVAC® should not be administered to individuals with a history of severe allergic reactions to any vaccine component, including neomycin. It is contraindicated in pregnant women, and women of childbearing age should avoid pregnancy for at least one month after vaccination. Individuals with compromised immune systems due to disease (e.g., HIV/AIDS with low CD4 counts, certain cancers) or medical therapies (e.g., immunosuppressive drugs, high-dose corticosteroids) should not receive the vaccine without medical supervision. Vaccination should be postponed in individuals with acute febrile illnesses. The vaccine should also not be given within 6 weeks (preferably 3 months) after receiving immunoglobulins or blood products.

Storage The freeze-dried vaccine should be stored in the dark at a temperature between 2-8°C. For long-term storage, -20°C is recommended for the lyophilized vaccine. The diluent should not be frozen but kept cool. After reconstitution, the vaccine should be used immediately and if not used, stored in the dark at 2-8°C for no longer than 6 hours.

Here are the most frequently asked questions about TRESIVAC INJ.(MMR) along with concise, accurate answers:

What is TRESIVAC INJ.(MMR) used for?

TRESIVAC INJ.(MMR) is a vaccine used for active immunization against three common and potentially serious viral infections: Measles, Mumps, and Rubella. It helps protect infants, children, adolescents, and young adults who are at risk of these diseases.

How does TRESIVAC INJ.(MMR) work?

TRESIVAC is a live attenuated vaccine, meaning it contains weakened forms of the measles, mumps, and rubella viruses. These weakened viruses are not strong enough to cause the diseases but stimulate the immune system to produce specific antibodies. This process builds active immunity, teaching the body to recognize and fight off the actual viruses if exposed in the future.

What is the usual dosage and administration?

TRESIVAC is administered as a single dose of 0.5 mL via subcutaneous injection. For children, the typical schedule includes a first dose at 9-12 months of age, a second dose between 15-18 months, and a third dose between 4-6 years of age. Adults who have not been vaccinated or are at high risk usually require two doses, administered at least 28 days apart, to ensure full immunity.

What are the possible side effects of TRESIVAC INJ.(MMR)?

Common side effects are usually mild and include pain, redness, or swelling at the injection site, mild fever, and a rash. Less common side effects can include loss of appetite, drowsiness, irritability, mild joint pain, swollen glands, muscle aches, and tingling sensations. Serious side effects, such as thrombocytopenia (low platelet count) or anaphylactic reactions, are rare.

Is TRESIVAC INJ.(MMR) safe during pregnancy or breastfeeding?

No, TRESIVAC INJ.(MMR) is not recommended for pregnant women due to a theoretical, though not demonstrated, teratogenic risk. Women should avoid becoming pregnant for at least one month (28 days) after receiving the vaccine. For breastfeeding women, there is limited data, and it is generally advised to consult a healthcare provider for personalized guidance.

Can TRESIVAC INJ.(MMR) be taken with other medications or vaccines?

TRESIVAC INJ.(MMR) can generally be administered alongside other vaccines (such as DTP, Polio, and Hepatitis B), but different injection sites should be used. However, it should not be given within 6 weeks (and ideally 3 months) after receiving immunoglobulins or blood products containing immunoglobulins, as these can interfere with the vaccine's effectiveness. Immunoglobulins should also not be administered within two weeks post-vaccination. It is also not recommended for individuals on immunosuppressive therapy, as they may not develop an optimal immune response.

What precautions should be taken before receiving TRESIVAC INJ.(MMR)?

Inform your healthcare provider if you have any allergies, especially to neomycin or eggs, or if you have immune system disorders, severe immunodeficiency (e.g., HIV/AIDS, leukemia), blood disorders, active untreated tuberculosis, or a history of convulsions. Vaccination may need to be postponed if you have an acute febrile illness.

What happens if a dose of TRESIVAC INJ.(MMR) is missed?

If a dose of TRESIVAC INJ.(MMR) is missed, it is important to consult your healthcare professional for guidance. The missed dose should be administered as soon as possible, ensuring a minimum interval of 28 days before the next scheduled dose to complete the vaccination series.

How should TRESIVAC INJ.(MMR) be stored?

The vaccine should be stored refrigerated at 2°C – 8°C and protected from light. For long-term storage, the freeze-dried vaccine can be kept at -20°C. The accompanying diluent should not be frozen but kept cool. After the vaccine is reconstituted, it should be used immediately. If not used immediately, it can be stored in the dark at 2-8°C for no longer than 6 hours before being discarded.